Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and
. Other Items. Forbearance Agreement On February 27, 2026, the Company entered into a Forbearance Agreement (the “Forbearance Agreement”) with (i) 100% of the l
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Second Amendment to Credit and Guaranty Agreement, dated February 27, 2026 104 Cove